Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.54)
# 307
Out of 4,667 analysts
116
Total ratings
46.15%
Success rate
40.89%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $194 → $236 | $317.09 | -25.57% | 11 | Nov 5, 2024 | |
| NVAX Novavax | Reiterates: Buy | $23 → $26 | $8.06 | +222.58% | 19 | Oct 10, 2024 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 | $2.77 | +116.61% | 2 | Oct 7, 2024 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $33 | $16.74 | +97.13% | 1 | Sep 19, 2024 | |
| HROW Harrow | Reiterates: Buy | $50 | $42.44 | +17.81% | 1 | Aug 29, 2024 | |
| ALT Altimmune | Reiterates: Buy | $20 | $8.05 | +148.45% | 9 | Aug 12, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $55 | $18.71 | +193.96% | 6 | Aug 12, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $29 → $34 | $31.15 | +9.15% | 13 | Aug 7, 2024 | |
| CGTX Cognition Therapeutics | Downgrades: Neutral | $5 → $1 | $0.44 | +127.27% | 2 | Aug 6, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | $18 → $5 | $3.28 | +52.44% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $49.86 | +84.52% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 | $0.61 | +229.06% | 5 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.38 | +18.34% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.56 | +608.47% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $24.42 | +55.61% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.34 | +781.32% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $2.67 | +5,892.51% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.66 | +201.20% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $26.05 | +68.91% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.57 | +5,632.48% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.64 | +523.64% | 1 | Jun 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $4.56 | +53.51% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $450 | $0.37 | +120,770.27% | 1 | Mar 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $90 | $0.21 | +42,962.20% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $3.36 | +7,935.71% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $16.17 | +376.19% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $2.96 | +48,548.65% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.82 | +42.10% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $84.07 | -53.61% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.95 | +464.10% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.31 | +688.86% | 1 | Mar 13, 2020 |
Madrigal Pharmaceuticals
Nov 5, 2024
Maintains: Neutral
Price Target: $194 → $236
Current: $317.09
Upside: -25.57%
Novavax
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $8.06
Upside: +222.58%
Trevi Therapeutics
Oct 7, 2024
Reiterates: Buy
Price Target: $6
Current: $2.77
Upside: +116.61%
Centessa Pharmaceuticals
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $16.74
Upside: +97.13%
Harrow
Aug 29, 2024
Reiterates: Buy
Price Target: $50
Current: $42.44
Upside: +17.81%
Altimmune
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $8.05
Upside: +148.45%
Arrowhead Pharmaceuticals
Aug 12, 2024
Reiterates: Buy
Price Target: $55
Current: $18.71
Upside: +193.96%
TG Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $31.15
Upside: +9.15%
Cognition Therapeutics
Aug 6, 2024
Downgrades: Neutral
Price Target: $5 → $1
Current: $0.44
Upside: +127.27%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $3.28
Upside: +52.44%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $49.86
Upside: +84.52%
Jan 31, 2024
Upgrades: Buy
Price Target: $2
Current: $0.61
Upside: +229.06%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $3.38
Upside: +18.34%
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $0.56
Upside: +608.47%
Sep 6, 2023
Initiates: Buy
Price Target: $38
Current: $24.42
Upside: +55.61%
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.34
Upside: +781.32%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $2.67
Upside: +5,892.51%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.66
Upside: +201.20%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $26.05
Upside: +68.91%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.57
Upside: +5,632.48%
Jun 14, 2022
Initiates: Buy
Price Target: $4
Current: $0.64
Upside: +523.64%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $4.56
Upside: +53.51%
Mar 29, 2022
Maintains: Buy
Price Target: $600 → $450
Current: $0.37
Upside: +120,770.27%
Jan 24, 2022
Maintains: Buy
Price Target: $195 → $90
Current: $0.21
Upside: +42,962.20%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $3.36
Upside: +7,935.71%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $16.17
Upside: +376.19%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $2.96
Upside: +48,548.65%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.82
Upside: +42.10%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $84.07
Upside: -53.61%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.95
Upside: +464.10%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.31
Upside: +688.86%